BACKGROUND: Calcific aortic valve disease (CAVD) is the most common cause of acquired valve disease. Initial phases of CAVD include thickening of the cusps, whereas advanced stages are associated with biomineralization and reduction of the aortic valve area. These conditions are known as aortic valve sclerosis (AVSc) and aortic valve stenosis (AVS), respectively. Because of its asymptomatic presentation, little is known about the molecular determinants of AVSc. The aim of this study was to correlate plasma and tissue osteopontin (OPN) levels with echocardiographic evaluation for the identification of asymptomatic patients at risk for CAVD. In addition, our aim was to analyze the differential expression and biological function of OPN splicing variants as biomarkers of early and late stages of CAVD. METHODS: From January 2010 to February 2011, 310 patients were enrolled in the study. Patients were divided into 3 groups based on transesophageal echocardiographic (TEE) evaluation: controls (56 patients), AVSc (90 patients), and AVS (164 patients). Plasma and tissue OPN levels were measured by immunohistochemical evaluation, enzyme-linked immunosorbent assay (ELISA), and real-time quantitative polymerase chain reaction (qPCR). RESULTS: Patients with AVSc and AVS have higher OPN levels compared with controls. OPN levels are elevated in asymptomatic patients with AVSc with no appearance of calcification during TEE evaluation. OPN splicing variants OPN-a, OPN-b, and OPN-c are differentially expressed during CAVD progression and are able to inhibit biomineralization in a cell-based biomineralization assay. CONCLUSIONS: The analysis of the differential expression of OPN splicing variants during CAVD may help in developing diagnostic and risk stratification tools to follow the progression of asymptomatic aortic valve degeneration.
BACKGROUND:Calcific aortic valve disease (CAVD) is the most common cause of acquired valve disease. Initial phases of CAVD include thickening of the cusps, whereas advanced stages are associated with biomineralization and reduction of the aortic valve area. These conditions are known as aortic valve sclerosis (AVSc) and aortic valve stenosis (AVS), respectively. Because of its asymptomatic presentation, little is known about the molecular determinants of AVSc. The aim of this study was to correlate plasma and tissue osteopontin (OPN) levels with echocardiographic evaluation for the identification of asymptomatic patients at risk for CAVD. In addition, our aim was to analyze the differential expression and biological function of OPN splicing variants as biomarkers of early and late stages of CAVD. METHODS: From January 2010 to February 2011, 310 patients were enrolled in the study. Patients were divided into 3 groups based on transesophageal echocardiographic (TEE) evaluation: controls (56 patients), AVSc (90 patients), and AVS (164 patients). Plasma and tissue OPN levels were measured by immunohistochemical evaluation, enzyme-linked immunosorbent assay (ELISA), and real-time quantitative polymerase chain reaction (qPCR). RESULTS:Patients with AVSc and AVS have higher OPN levels compared with controls. OPN levels are elevated in asymptomatic patients with AVSc with no appearance of calcification during TEE evaluation. OPN splicing variants OPN-a, OPN-b, and OPN-c are differentially expressed during CAVD progression and are able to inhibit biomineralization in a cell-based biomineralization assay. CONCLUSIONS: The analysis of the differential expression of OPN splicing variants during CAVD may help in developing diagnostic and risk stratification tools to follow the progression of asymptomatic aortic valve degeneration.
Authors: Marco Antonio Perin; Fábio Sândoli de Brito; Breno Oliveira Almeida; Marco Aurélio M Pereira; Alexandre Abizaid; Flávio Tarasoutchi; Eberhard Grube Journal: Arq Bras Cardiol Date: 2009-09 Impact factor: 2.000
Authors: John E Cosmi; Smadar Kort; Paul A Tunick; Barry P Rosenzweig; Robin S Freedberg; Edward S Katz; Robert M Applebaum; Itzhak Kronzon Journal: Arch Intern Med Date: 2002-11-11
Authors: Salma Ayoub; Giovanni Ferrari; Robert C Gorman; Joseph H Gorman; Frederick J Schoen; Michael S Sacks Journal: Compr Physiol Date: 2016-09-15 Impact factor: 9.090
Authors: Kathryn H Driesbaugh; Emanuela Branchetti; Juan B Grau; Samuel J Keeney; Kimberly Glass; Mark A Oyama; Nancy Rioux; Salma Ayoub; Michael S Sacks; John Quackenbush; Robert J Levy; Giovanni Ferrari Journal: J Mol Cell Cardiol Date: 2017-12-30 Impact factor: 5.000
Authors: Rachana Sainger; Juan B Grau; Emanuela Branchetti; Paolo Poggio; Eric Lai; Erblina Koka; William J Vernick; Robert C Gorman; Joseph E Bavaria; Giovanni Ferrari Journal: J Heart Valve Dis Date: 2013-03
Authors: Emanuela Branchetti; Rachana Sainger; Paolo Poggio; Juan B Grau; Jeffrey Patterson-Fortin; Joseph E Bavaria; Michael Chorny; Eric Lai; Robert C Gorman; Robert J Levy; Giovanni Ferrari Journal: Arterioscler Thromb Vasc Biol Date: 2012-12-13 Impact factor: 8.311
Authors: Paolo Poggio; Rachana Sainger; Emanuela Branchetti; Juan B Grau; Eric K Lai; Robert C Gorman; Michael S Sacks; Alessandro Parolari; Joseph E Bavaria; Giovanni Ferrari Journal: Cardiovasc Res Date: 2013-03-12 Impact factor: 10.787
Authors: Alexander P Kossar; Wanda Anselmo; Juan B Grau; Yichuan Liu; Aeron Small; Samuel L Carter; Lisa Salvador; Lei Zhao; Mary Ellen Cvijic; Zhuyin Li; Melissa Yarde; Nancy Rioux; Daniel J Rader; Robert J Levy; Giovanni Ferrari Journal: Physiol Genomics Date: 2020-02-24 Impact factor: 3.107